KES 7 Capital

KES 7 Capital is a Canadian merchant bank and investment firm that provides financial advisory and capital solutions to growth-stage companies, with a significant focus on the healthcare and life sciences sectors. The firm specializes in identifying high-potential opportunities and providing the strategic and financial support necessary to scale operations and navigate capital markets. KES 7 has been instrumental in the development and financing of several prominent Canadian healthcare entities, including HLS Therapeutics and Antibe Therapeutics. By leveraging its extensive network and deep expertise in investment banking, the firm assists its portfolio companies with complex transactions, including mergers and acquisitions and private placements. KES 7 typically targets late-stage private or early-stage public companies where it can act as a value-added partner. The firm was founded by Kevin Sullivan, the former CEO of GMP Securities, bringing significant capital markets experience to the biotech and specialty pharma space.